(NASDAQ: CELC) Celcuity's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Celcuity's revenue in 2024 is $0.On average, 3 Wall Street analysts forecast CELC's revenue for 2026 to be $1,536,359,904, with the lowest CELC revenue forecast at $741,533,472, and the highest CELC revenue forecast at $2,326,618,368. On average, 3 Wall Street analysts forecast CELC's revenue for 2027 to be $7,308,931,519, with the lowest CELC revenue forecast at $6,165,843,206, and the highest CELC revenue forecast at $8,860,335,264.
In 2028, CELC is forecast to generate $13,028,545,158 in revenue, with the lowest revenue forecast at $10,485,922,810 and the highest revenue forecast at $16,037,831,117.